☰

Kristin M. Bompiani, Ph.D. - Publications

Affiliations: 
2012 Genetics and Genomics Duke University, Durham, NC 
Area:
Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Gunaratne R, Kumar S, Frederiksen JW, Stayrook S, Lohrmann JL, Perry K, Bompiani KM, Chabata CV, Thalji NK, Ho MD, Arepally G, Camire RM, Krishnaswamy S, Sullenger BA. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology. PMID 29863725 DOI: 10.1038/Nbt.4153  0.661
2016 Kahsai AW, Wisler JW, Lee J, Ahn S, Cahill Iii TJ, Dennison SM, Staus DP, Thomsen AR, Anasti KM, Pani B, Wingler LM, Desai H, Bompiani KM, Strachan RT, Qin X, et al. Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nature Chemical Biology. PMID 27398998 DOI: 10.1038/Nchembio.2126  0.602
2016 Bompiani KM, Caglic D, Krutein MC, Benoni G, Hrones M, Lairson LL, Bian H, Smith GR, Dickerson TJ. High-Throughput Screening Uncovers Novel Botulinum Neurotoxin Inhibitor Chemotypes. Acs Combinatorial Science. PMID 27314875 DOI: 10.1021/Acscombsci.6B00033  0.335
2015 Soule EE, Bompiani KM, Woodruff RS, Sullenger BA. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Therapeutics. PMID 26584417 DOI: 10.1089/nat.2015.0565  0.667
2014 Bompiani KM, Lohrmann JL, Pitoc GA, Frederiksen JW, Mackensen GB, Sullenger BA. Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chemistry & Biology. 21: 935-44. PMID 25065530 DOI: 10.1016/J.Chembiol.2014.05.016  0.607
2012 Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis : Jth. 10: 870-80. PMID 22385910 DOI: 10.1111/J.1538-7836.2012.04679.X  0.673
2012 Bompiani KM, Woodruff RS, Becker RC, Nimjee SM, Sullenger BA. Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Current Pharmaceutical Biotechnology. 13: 1924-34. PMID 22352726 DOI: 10.2174/138920112802273137  0.697
2012 Rangnekar A, Zhang AM, Li SS, Bompiani KM, Hansen MN, Gothelf KV, Sullenger BA, LaBean TH. Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 673-81. PMID 21889476 DOI: 10.1016/J.Nano.2011.08.011  0.596
2010 Hansen MN, Zhang AM, Rangnekar A, Bompiani KM, Carter JD, Gothelf KV, LaBean TH. Weave tile architecture construction strategy for DNA nanotechnology. Journal of the American Chemical Society. 132: 14481-6. PMID 20863133 DOI: 10.1021/Ja104456P  0.331
2009 Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna (New York, N.Y.). 15: 2105-11. PMID 19846574 DOI: 10.1261/Rna.1240109  0.655
2009 Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/Nm.1990  0.576
Show low-probability matches.